Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02764567 · ClinicalTrials.gov registry record · NA
Essential Oil Aromatherapy Intervention
A NA study, sponsored by HealthEast Care System.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT02764567: Completed NA study, sponsored by HealthEast Care System.
NCT02764567 is a NA study that has completed, run by HealthEast Care System. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02764567, a NA study, has completed, sponsored by HealthEast Care System.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
Lab sampling for clinical trial participants can be a stressful and painful experience. Most trial participants will have blood drawn for lab samples at multiple study visits. The participants must fast for up to ten hours before the blood sampling, in many cases, and patients often report a painful experience if more than one venipuncture occurs. In addition, the number of collection tubes can increase the anxiety level of the patient and the phlebotomist. This project proposes to evaluate if essential oil aromatherapy results in less pain and /or anxiety when compared to usual care.
Interventions
- OTHER Essential Oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-12 |
| Phase | NA |
What the finished NCT02764567 record still lists
NCT02764567 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Essential Oil is the first listed.
NCT02764567 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02764567 about?
NCT02764567 is a clinical study titled "Essential Oil Aromatherapy Intervention". Lab sampling for clinical trial participants can be a stressful and painful experience. Most trial participants will have blood drawn for lab samples at multiple study visits. The participants must fast for up to ten hours before the blood sampling, in many cases, and patients often report a painful...
What is the current status of trial NCT02764567?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2016-05. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02764567?
The interventions under investigation include: Essential Oil (OTHER).
Who is sponsoring clinical trial NCT02764567?
This trial is sponsored by HealthEast Care System, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02764567's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia